BRIEF

on VALBIOTIS (EPA:ALVAL)

Valbiotis to Launch ValbiotisPRO® Cardio-circulation on 2 June

Stock price chart of VALBIOTIS (EPA:ALVAL) showing fluctuations.

Valbiotis, a French laboratory known for developing scientifically validated dietary supplements, will introduce ValbiotisPRO® Cardio-circulation on June 2. This product targets high blood pressure and poor circulation issues, such as heavy legs and tingling sensations. Using a 100% natural formula called Tensodrive®, developed with La Rochelle University, Clermont Auvergne University, and CNRS, the supplement has undergone extensive clinical research.

This launch marks the third addition to the ValbiotisPRO® range, following previous releases focused on cholesterol and metabolic health. Available in French pharmacies and online, the product aims to enhance Valbiotis’s presence in multichannel markets. New listings with supplemental insurance companies like Nostrum Care and Elsee Care bolster this strategy.

Sébastien Poncet, Director at Valbiotis, highlights the launch as a step to expand their cardiometabolic solutions portfolio, underpinned by robust marketing strategies and health professional training programs.

R. H.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all VALBIOTIS news